Literature DB >> 30730231

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.

Idanna Innocenti1, Francesca Morelli2,3, Francesco Autore2,3, Andrea Corbingi1, Raffaella Pasquale4, Federica Sorà1, Maurizio Pompili5, Luca Laurenti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30730231     DOI： 10.1080/10428194.2018.1523401

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

1.  B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.

Authors:  Zhiquan Wang; Huihuang Yan; Justin C Boysen; Charla R Secreto; Renee C Tschumper; Dania Ali; Qianqian Guo; Jian Zhong; Jiaqi Zhou; Haiyun Gan; Chuanhe Yu; Diane F Jelinek; Susan L Slager; Sameer A Parikh; Esteban Braggio; Neil E Kay
Journal:  Blood Cancer J       Date:  2022-07-01       Impact factor: 9.812

Review 2.  Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.

Authors:  Daniel Rivera; Alessandra Ferrajoli
Journal:  Curr Oncol Rep       Date:  2022-04-02       Impact factor: 5.945

3.  Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.

Authors:  Idanna Innocenti; Gianluigi Reda; Andrea Visentin; Marta Coscia; Marina Motta; Roberta Murru; Riccardo Moia; Massimo Gentile; Elsa Pennese; Francesca Maria Quaglia; Francesco Albano; Ramona Cassin; Marina Deodato; Claudia Ielo; Anna Maria Frustaci; Alfonso Piciocchi; Arianna Rughini; Valentina Arena; Daniela Di Sevo; Annamaria Tomasso; Francesco Autore; Giovanni Del Poeta; Lydia Scarfò; Francesca Romana Mauro; Alessandra Tedeschi; Livio Trentin; Maurizio Pompili; Robin Foà; Paolo Ghia; Antonio Cuneo; Luca Laurenti
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

4.  Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors:  Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 5.  Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yibo Wu; He Huang; Yi Luo
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.